A Message from the President and CEO
AS A GLOBAL LEADER in orthopedics and rheumatology, HSS has always had as our primary goal to provide our patients with the highest-quality care. In 2021, we made great strides in improving outcomes, increasing access, and advancing care for the most challenging orthopaedic and rheumatologic conditions. At HSS, innovation is in our DNA and that mindset has driven many of these advances in 2021.
It is also our goal to share our deep expertise with patients and practitioners everywhere so that everyone can benefit from our knowledge base. To do so, we’ve continued to seek ways to expand our impact, embarking on new digital initiatives and partnerships with organizations throughout the country and around the world.
Meanwhile, we also made significant progress on an exciting transformation of our main campus in Manhattan, at the heart of which is the construction of the Anna-Maria and Stephen Kellen Tower (right), a brand-new clinical building rising over the FDR Drive. The HSS Kellen Tower, on track to open in 2024, will allow us to expand care for joint replacement and spine conditions with private inpatient floors, physician offices and exam rooms and imaging.
We are also seeking novel ways to enhance quality and efficiency across the total episode of care. Musculoskeletal issues are among the leading causes of disability as well the fastest-growing segments of healthcare costs. It is imperative that as the leaders in our field, we be responsible stewards of healthcare and set the standards that can help guide other organizations toward more efficient, high-quality care.
We enhance quality and efficiency simultaneously…by matching individual patients with precisely the right amount of care at precisely the right time
One of the many ways we enhance quality and efficiency simultaneously is by matching individual patients with precisely the right amount of care at precisely the right time. In the context of complex care, that often means identifying patients who are at risk for adverse outcomes due to prior surgeries, obesity, a history of opioid misuse or other factors. In doing so, we can recommend tailored interventions to ensure each patient is as fit as possible before they ever enter an operating room. It’s ongoing initiatives like these that drive down our already extremely low complication and readmission rates—which is a result that truly benefits everyone.
None of this progress would have been possible without the dedication of our entire HSS family throughout what we all know have been challenging times. I hope that you will take a moment to learn more about the progress we made in adult orthopaedics, pediatric orthopaedics and rheumatology in 2021, and I wish us all the best in the year ahead.